Innovative Eyewear, Inc. received a written notice from Nasdaq’s Listing Qualifications Department that its common stock failed the $1.00 minimum bid-price requirement after closing below that level for 30 consecutive business days. The notice has no immediate effect on the Nasdaq Capital Market listing. The company has until April 7, 2027, a 180-calendar-day compliance period, to meet the requirement by closing at or above $1.00 for at least 10 consecutive business days; Nasdaq staff may extend the 10-day period.
If the company does not regain compliance, it may qualify for a second 180-calendar-day period if it meets initial-listing criteria other than the bid-price requirement, satisfies the continued-listing requirement for market value of publicly held shares, and gives Nasdaq written notice of its intent to cure, including through a reverse stock split if necessary. If it is ineligible for that period or appears unable to cure the deficiency, Nasdaq may issue a delisting notice. A timely hearing request would stay further suspension or delisting action pending the hearing process and any extension granted by the Panel.
Innovative Eyewear (LUCY) reported preliminary, unaudited net sales for the third quarter ended September 30, 2026; management described them as the highest quarterly net sales in company history. The estimates remain subject to completion of quarter-end close procedures and review of interim financial statements, and actual results may differ materially.
During the quarter, the company opened three wholesale and international channels: a major U.S. big-box retailer, FYihealth Group in Canada, and Directed Electronics in Australia and New Zealand. The company plans to launch Lucyd Aero for holiday 2026 and expects to report full third-quarter results in mid-November 2026.
Innovative Eyewear, Inc. (LUCY) asks shareholders to elect Harrison Gross, Kristen McLaughlin, Louis Castro and Olivia C. Bartlett as directors, ratify Cherry Bekaert LLP for fiscal 2026, and approve a reverse stock split of 1-for-2 to 1-for-12. If approved, the board may decide whether and when to implement the split and select the ratio, provided it is effected within one year of shareholder approval. The 2026 annual meeting is scheduled for November 16, 2026. Holders of the 8,712,263 shares outstanding on September 21, 2026, are eligible to vote, subject to the control-share voting provisions.
The split would leave the 50,000,000 authorized common shares unchanged, and the company says it has no current plans to issue the potentially newly available shares. The board unanimously recommends voting FOR the director nominees and both other proposals.
Innovative Eyewear Inc (LUCY) received a Rule 144 notice indicating that officer Joaquin Abondano, through Raymond James & Associates, Inc., plans to sell 3,912 shares of common stock, with an aggregate market value of $3,376.14, on or about September 18, 2026. The notice states that 8,600,000 shares of this class were outstanding. It also lists an RSU grant of 14,800 common shares dated August 19, 2026, and discloses that Abondano sold 5,020 shares over the past three months for proceeds of $3,288.00.
Innovative Eyewear Inc (LUCY) is the issuer for a planned resale of its common stock under Rule 144 by Joaquin Abondano, identified as an officer. The notice covers a potential sale of up to 14,800 shares of common stock, originally received as an RSU grant, with Raymond James & Associates acting as broker.
The filing also reports that Abondano sold 5,020 shares of Innovative Eyewear common stock during the past three months for total proceeds of 3,288.00. The sales are to be made for cash on Nasdaq.
Innovative Eyewear Inc (LUCY) reported that Chief Financial Officer Gayle Oswald received two grants of 16,233 shares of common stock on April 2, 2026 and August 19, 2026 at $0.00 per share. On the same respective dates, she sold 7,574 shares at a $1.0725 average price and 7,959 shares at a $0.6745 average price in open market or private transactions. The filing’s Rule 10b5-1 checkbox is not marked as being pursuant to a trading plan, and it does not state her total holdings after these transactions.
Innovative Eyewear Inc (LUCY) reported insider equity activity by Chief AI & Growth Officer Konrad Dabrowski. He received grants of 20,900 shares of common stock on April 2, 2026 and August 19, 2026, each at no cost, and sold 6,692 shares on April 2 at $1.0581 per share and 6,935 shares on August 19 at a weighted-average price of $0.6911 per share in open-market or private transactions. Post-transaction holdings were not provided.
Innovative Eyewear Inc (LUCY) reported insider equity activity by Chief Operating Officer Joaquin Abondano. On April 2 and August 19, 2026, he received two grants of 14,800 Common Shares each at $0.00 per share as awards. On the same dates, he sold 4,779 shares at $1.0501 per share and 5,020 shares at an average of $0.6765 per share in open-market or private transactions. The August 19 price is disclosed as a weighted average, with detailed trade breakdowns available on request. The filing states these transactions were not conducted under a Rule 10b5-1 trading plan.
Innovative Eyewear Inc (LUCY) reported that Chief Executive Officer and director Harrison R. Gross had both awards and sales of Common Stock. On April 2, 2026 and August 19, 2026, he received 24,600 shares on each date as a grant or award at $0.00 per share. On those same dates he sold shares in open market or private transactions, including 13,764 shares at an average price of $1.0658, 8,252 shares at an average price of $0.6916, and 5,722 shares at an average price of $0.705, with each price disclosed as a weighted average over multiple trades.
Innovative Eyewear Inc (symbol LUCY) is the issuer for a notice of proposed sale of securities filed on behalf of officer David Eric Cohen under Rule 144. The notice covers a planned sale of up to 18,200 shares of common stock, expected on or about 08/19/2026, through Raymond James & Associates, Inc. The shares are described as originating from an RSU Grant by the issuer, with cash as the form of payment. The filing also reports that Cohen sold 1,860 shares of common stock on 07/06/2026 during the prior three months.